Publications by authors named "N G M Thielen"
Article Synopsis
- The IMWG frailty index shows that frailty levels in patients undergoing anti-myeloma treatment can change frequently over time.
- Assessing frailty dynamically during treatment provides better predictions for survival and early mortality than just looking at initial frailty levels.
- The study references two clinical trials, HOVON 143 (NTR6297) and HOVON 123 (NTR4244), related to this research.
Article Synopsis
- The study aimed to differentiate osteoarthritis (OA) patients by analyzing their serum-induced cellular signaling patterns, using samples from knee OA patients, hand OA patients, and healthy controls.
- Results showed significant differences in cellular pathway activity based on the type of OA, with hand OA serum triggering higher MAPK-related AP1 activity, while knee OA serum affected other pathways related to ELK1-SRF, STAT1-STAT2, and SOX9.
- The findings suggest that the underlying mechanisms of OA differ between hand and knee OA, potentially paving the way for more targeted treatments based on specific OA endotypes.
With the increasing prevalence of comorbidity in an ageing population, it is crucial to better understand the impact of comorbidity on health-related quality of life (HRQoL) after lymphoma or multiple myeloma (MM) diagnosis. We included 261 newly diagnosed patients (67% response rate) diagnosed with lymphoma or MM between October 2020 and March 2023 in a longitudinal survey. The European Organisation for Research and Treatment of Cancer (EORTC) questionnaires were used to measure generic and disease-specific HRQoL.
View Article and Find Full Text PDFPurpose: To investigate the proportion of patients with lymphoma with persistent clinically relevant cognitive impairment, and its relation to treatment, fatigue, and psychological distress.
Methods: Patients with diffuse-large-B-cell-lymphoma (DLBCL), follicular-lymphoma (FL), and chronic-lymphocytic-leukemia (CLL)/small-lymphocytic-lymphoma (SLL), diagnosed between 2004-2010 or 2015-2019, were followed up to 8 years post-diagnosis. Sociodemographic and clinical data were obtained from the Netherlands Cancer Registry and the Population-based HAematological Registry for Observational Studies.
Background: The outcome of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study was to prospectively investigate the efficacy and safety of Ixazomib-Daratumumab-low-dose dexamethasone (Ixa-Dara-dex) in NDMM intermediate-fit patients.
Methods: In this phase II multicenter HOVON-143 study, IMWG Frailty index based intermediate-fit patients, were treated with 9 induction cycles of Ixa-Dara-dex, followed by maintenance with ID for a maximum of 2 years.